- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940322
Moses Technology vs Vapor Tunnel in Low Power Laser Lithotripsy (MT VT)
Double Blind Randomized Controlled Trial Comparing Two Distinct Pulse Modulation Modes in Low Power Laser Lithotripsy
The goal of this clinical study is to compare two different laser settings used to break up kidney and ureter stones during surgery. The study will include adults with kidney or ureter stones who are scheduled to undergo a procedure in which an endoscope is passed through the urinary tract and a laser is used to break the stones into smaller pieces.
The main question is whether one laser setting can break up stones using less energy than the other, while maintaining similar treatment effectiveness and safety.
A total of 110 participants will be randomly assigned to one of two groups:
- One group will undergo stone treatment using Moses Technology.
- The other group will undergo stone treatment using Vapor Tunnel.
Both methods use a laser to break stones into smaller pieces. The study will compare the amount of laser energy used in relation to the size of the stone. Researchers will also assess the duration of the procedure, how completely the stones are cleared, the movement of stones during surgery, and any complications.
The findings may help urologists understand which laser setting is more efficient and whether it offers advantages during the treatment of kidney and ureter stones.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Polyvios Arseniou
- Phone Number: 00306987553988
- Email: parseniou136@gmail.com
Study Contact Backup
- Name: Lazaros Tzelves
- Phone Number: 00306944104974
- Email: lazarostzelves@gmail.com
Study Locations
-
-
Attica
-
Marousi, Attica, Greece, 15126
- 2nd Department of Urology, Sismanogleio General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- kidney/ureter stone
- maximum stone diameter 5-20 mm (CT)
- any stone composition
- recent CT (3 months prior to procedure)
- indication/no contraindications for laser lithotripsy
- negative urine culture/adequate antibiotic preparation
- informed consent
Exclusion Criteria:
- pregnancy
- inability/unwillingness to provide informed consent
- radiolucent stones
- ipsilateral urinary tract anatomical abnormalities
- previous non-endoscopic surgery on the urinary tract
- active urinary tract infection
- acute kidney injury
- bleeding disorders
- inability to discontinue antithrombotic medication when required for the procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Moses Technology
|
Laser lithotripsy using Moses Technology pulse modulation by Lumenis Pulse 120H Ho:YAG laser system, that produces a two-part laser pulse. The first low-energy part produces a vapor cavity through which the second high-energy part is transmitted to the stone without energy loss, increasing laser efficacy.
Other Names:
|
|
Active Comparator: Vapor Tunnel
|
Laser lithotripsy using Vapor Tunnel pulse modulation by Quanta Cyber Ho Ho:YAG laser system, which creates one low-power long-length laser pulse that prevents stone retropulsion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Laser efficacy
Time Frame: During ureteroscopic procedure
|
Total energy delivered by the Ho:YAG laser during stone lithotripsy, divided by the preoperative stone volume measured on computed tomography (CT). The result will be expressed in joules per cubic millimeter (J/mm³). |
During ureteroscopic procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Laser-on time
Time Frame: During ureteroscopic procedure
|
The cumulative duration of laser activation during stone lithotripsy, measured in minutes and recorded by the laser system. |
During ureteroscopic procedure
|
|
Operative time
Time Frame: During ureteroscopic procedure
|
The total duration of the ureteroscopic procedure, measured in minutes from the beginning to the completion of the surgical procedure. |
During ureteroscopic procedure
|
|
Total energy
Time Frame: During ureteroscopic procedure
|
The cumulative energy delivered by the Ho:YAG laser during stone lithotripsy, measured in joules (J) and recorded by the laser system. |
During ureteroscopic procedure
|
|
Lithotripsy rate
Time Frame: During ureteroscopic procedure
|
Lithotripsy rate calculated as the preoperative stone volume, measured on CT in cubic millimeters, divided by the total laser activation time in seconds. Results will be expressed in mm³/s. |
During ureteroscopic procedure
|
|
Stone-free rate
Time Frame: One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)
|
The proportion of patients with no residual stone fragments larger than 3 mm on postoperative computed tomography (CT). |
One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intraoperative complications
Time Frame: During ureteroscopic procedure
|
The proportion of patients experiencing one or more complications during the ureteroscopic procedure, including their type and nature. |
During ureteroscopic procedure
|
|
Postoperative complications
Time Frame: Within 30 days after the ureteroscopic procedure
|
The proportion of patients experiencing postoperative complications, including their type and severity, classified according to the Clavien-Dindo classification system. |
Within 30 days after the ureteroscopic procedure
|
|
Length of hospital stay
Time Frame: From hospital admission until discharge
|
The duration of hospitalization, calculated as the number of days from hospital admission to hospital discharge. |
From hospital admission until discharge
|
|
Stone retropulsion
Time Frame: During ureteroscopic procedure
|
Surgeon-assessed stone retropulsion during laser lithotripsy, evaluated according to the distance of stone displacement, frequency of retropulsion events, and impact of retropulsion on the completion of stone fragmentation. |
During ureteroscopic procedure
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Ventimiglia E, Traxer O. What Is Moses Effect: A Historical Perspective. J Endourol. 2019 May;33(5):353-357. doi: 10.1089/end.2019.0012.
- Mullerad M, Aguinaga JRA, Aro T, Kastin A, Goldin O, Kravtsov A, Assadi A, Badaan S, Amiel GE. Initial Clinical Experience with a Modulated Holmium Laser Pulse-Moses Technology: Does It Enhance Laser Lithotripsy Efficacy? Rambam Maimonides Med J. 2017 Oct 16;8(4):e0038. doi: 10.5041/RMMJ.10315.
- Ulvik O, AEsoy MS, Juliebo-Jones P, Gjengsto P, Beisland C. Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022 Jul;82(1):73-79. doi: 10.1016/j.eururo.2022.02.027. Epub 2022 Mar 14.
- Terry RS, Ho DS, Scialabba DM, Whelan PS, Qi R, Ketterman BT, Preminger GM, Zhong P, Lipkin ME. Comparison of Different Pulse Modulation Modes for Holmium:Yttrium-Aluminum-Garnet Laser Lithotripsy Ablation in a Benchtop Model. J Endourol. 2022 Jan;36(1):29-37. doi: 10.1089/end.2021.0113. Epub 2021 Oct 29.
- Rico L, Contreras P, Blas L, Butori S, Martinez E, Proietti S, Giusti G, Ameri C. Dusting efficacy between the regular setting of holmium laser (Ho:YAG) versus Vapor Tunnel pulse modality for non-complex kidney stones. Lasers Med Sci. 2023 Jul 28;38(1):168. doi: 10.1007/s10103-023-03828-9.
- Kim K, Seo YS, Chung PS, Eom JB. Analysis of lithotripsy efficiency and stone retropulsion displacement according to pulse characteristics of Ho: YAG laser with Moses effect. Lasers Surg Med. 2024 Feb;56(2):197-205. doi: 10.1002/lsm.23743. Epub 2023 Nov 30.
- Corsini C, Robesti D, Villa L, Montorsi F, Pietropaolo A, Panthier F, Sierra A, Juliebo-Jones P, Kwok JL, Tsaturyan A, Contreras P, Fossati N, Gallina A, Xavier Keller E, Knoll T, Kartalas Goumas I, Somani BK, Traxer O, Salonia A, Ventimiglia E. Is Pulse Modulation the Future of Laser Technology in Endourology: Evidence from a Literature Review - Section of EAU Endourology. Eur Urol Focus. 2025 Mar;11(2):347-355. doi: 10.1016/j.euf.2024.10.009. Epub 2024 Nov 13.
- Black KM, Aldoukhi AH, Teichman JMH, Majdalany SE, Hall TL, Roberts WW, Ghani KR. Pulse modulation with Moses technology improves popcorn laser lithotripsy. World J Urol. 2021 Jun;39(6):1699-1705. doi: 10.1007/s00345-020-03282-0. Epub 2020 Jun 6.
- Aldoukhi AH, Roberts WW, Hall TL, Ghani KR. Watch Your Distance: The Role of Laser Fiber Working Distance on Fragmentation When Altering Pulse Width or Modulation. J Endourol. 2019 Feb;33(2):120-126. doi: 10.1089/end.2018.0572.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Calculi
- Pathological Conditions, Anatomical
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Pathological Conditions, Signs and Symptoms
- Urinary Calculi
- Urolithiasis
- Therapeutics
- Surgical Procedures, Operative
- Laser Therapy
- Ablation Techniques
- Ultrasonic Surgical Procedures
- Lithotripsy
- Lithotripsy, Laser
Other Study ID Numbers
- 88866-24/7/2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.